Northbridge Financial Group LLC Takes $2.55 Million Position in Eli Lilly and Company $LLY

Northbridge Financial Group LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, Holdings Channel.com reports. The firm purchased 2,370 shares of the company’s stock, valued at approximately $2,547,000. Eli Lilly and Company accounts for approximately 1.1% of Northbridge Financial Group LLC’s holdings, making the stock its 16th biggest position.

Several other hedge funds also recently modified their holdings of the company. First Business Financial Services Inc. increased its holdings in shares of Eli Lilly and Company by 2.1% during the fourth quarter. First Business Financial Services Inc. now owns 5,719 shares of the company’s stock worth $6,146,000 after buying an additional 118 shares in the last quarter. Banque Cantonale Vaudoise raised its holdings in Eli Lilly and Company by 1.0% in the fourth quarter. Banque Cantonale Vaudoise now owns 21,254 shares of the company’s stock worth $22,841,000 after purchasing an additional 211 shares during the period. Hardy Reed LLC raised its holdings in Eli Lilly and Company by 6.8% in the fourth quarter. Hardy Reed LLC now owns 1,286 shares of the company’s stock worth $1,382,000 after purchasing an additional 82 shares during the period. Jag Capital Management LLC lifted its position in Eli Lilly and Company by 55.1% in the 4th quarter. Jag Capital Management LLC now owns 21,051 shares of the company’s stock valued at $22,623,000 after acquiring an additional 7,481 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. lifted its position in Eli Lilly and Company by 52.9% in the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 2,600 shares of the company’s stock valued at $2,794,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Daiwa Securities Group increased their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Scotiabank restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,218.33.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary continue to highlight Eli Lilly’s leadership in the obesity boom, with strong sales momentum in key products such as Mounjaro and broader confidence that the company still has room to run. Article Title
• Positive Sentiment: Stat News reported that Eli Lilly tops prominent rankings for pharma R&D performance, reinforcing the view that the company’s pipeline and innovation engine remain among the best in the industry. Article Title
• Positive Sentiment: Eli Lilly also announced it completed a key olomorasib drug-interaction study, which helps clarify next steps for its KRAS pipeline and supports the long-term growth story beyond obesity drugs. Article Title
• Neutral Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations event that could provide more details on strategy and pipeline updates. Article Title
• Negative Sentiment: The U.S. Supreme Court declined to hear Eli Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million award and keeping legal/compliance risk in focus. Article Title
• Negative Sentiment: Related coverage noted that the ruling could raise scrutiny around Medicaid rebates and dividend implications, adding a modest overhang even as the core business remains strong. Article Title

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,017.68 on Wednesday. The company has a fifty day moving average of $940.54 and a 200-day moving average of $1,000.84. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $958.39 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.